Hemo Organic Ltd to consider unaudited Q1 FY2026 results at board meeting on July 15

What Hemo Organic Ltd announced

Hemo Organic Ltd (BSE: 524590) informed the Bombay Stock Exchange that its Board of Directors will convene on 15 July 2026. The primary purpose of the meeting is to consider and approve the unaudited financial results for the quarter ended 30 June 2026, together with the accompanying limited review report. The filing, submitted on 10 July 2026, also notes that the board will address any other business items circulated in the agenda.

Board meeting agenda

The agenda, as outlined in the intimation, comprises two main items:

1. Unaudited Financial Results – The board will review the financial statements for the quarter ended 30 June 2026. These results are unaudited, meaning they have not yet undergone a full statutory audit.
2. Limited Review Report – A limited review, which is a less extensive examination than a full audit, will be presented alongside the unaudited results. The report provides limited assurance on the accuracy of the financial information.

The filing also mentions that the board may transact other business as per the detailed agenda, though no further specifics are disclosed.

Key facts at a glance

Why this matters for investors

The meeting is a routine governance step that allows shareholders to gauge the company's short‑term performance before the results are audited. Approval of unaudited results signals that management is confident in the numbers, while the limited review provides a modest level of assurance. Investors typically monitor such filings to anticipate when audited results may be released and to assess any material changes in the company's financial position.

Conclusion

Hemo Organic Ltd’s board will meet on 15 July 2026 to approve its unaudited Q1 FY2026 financial results and the accompanying limited review report. Apart from these items, the board may address additional matters listed in the agenda. No further financial details were disclosed in the filing, and the outcomes will be communicated in subsequent disclosures.